{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for "Industrial Aid[C45678]|Reagent[C802]|Imaging Agent[C1966]|Contrast Agent[C390]" in comments (approximate match)
Status:
Possibly Marketed Outside US
Source:
NCT01255722: Phase 4 Interventional Completed Coronary Artery Disease
(2010)
Source URL:
Class (Stereo):
CHEMICAL (MIXED)
Conditions:
Iobitridol is a contrast medium used for intravenous urography, cerebral computed tomography, computed tomography of the whole body, digital subtraction angiography, arteriography, angiocardiography, venography, CT scan of the thorax. The drug is marketed under the name Xenetix.
Status:
Possibly Marketed Outside US
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
Iocarmic acid is a molecule used in seventies as a contrast media for myelography. Iocarmate meglumine (Dimer-X), a water-soluble salt of iocarmic acid was reported to be safe and best tolerated by central nervous system compared to metrizamide in a double-blind test in patients with symptoms of lumbar and sacral root involvement. In the experimental and clinical studies of Dimer-X used for ventriculography the apparent superiority of Dimer-X over Conray 60 and Angiografin as far as side effects were concerned was demonstrated, but there were no particular differences in the intensities of the ventriculograms obtained. Morphological studies of the ventricles and histological examinations of the ventricular walls 1 month after injections of Dimer-X into the ventricles of dogs showed no abnormalities. In the clinical studies, ventriculography Dimer-X, performed on patients with diseases of the central nervous system, produced ventriculograms of good diagnostic value with no side effects, such as convulsions, apart from mild headache or vomiting in 4 instances. Ventriculography with Dimer-X was carried in 15 infants with myelomeningocele and progressive hydrocephalus. However, as was shown in a number of studies iocarmate produced moderate to severe arachnoiditis from myelography in primates. Early meningitis side effects following lumbar radiculography with iocarmate meglumine were demonstrated.
Status:
US Previously Marketed
Source:
PANTOPAQUE by ALCON
(1944)
Source URL:
First approved in 1944
Source:
PANTOPAQUE by ALCON
Source URL:
Class:
MIXTURE
Status:
US Approved Rx
(2019)
Source:
ANDA210016
(2019)
Source URL:
First approved in 1988
Source:
MAGNEVIST by BAYER HLTHCARE
Source URL:
Class (Stereo):
CHEMICAL (RACEMIC)
Conditions:
DOTAREM (Gadoterate Meglumine ) is a gadolinium-based contrast agent indicated for intravenous use with magnetic resonance imaging (MRI) in brain (intracranial), spine and associatedtissues in adult and pediatric patients (2 years of age and older) to detect and visualize areas with disruption of the blood brain barrier (BBB) and/or abnormal vascularity. Gadoterate Meglumine is a gadolinium chelate paramagnetic contrast agent. When placed in a magnetic field, gadoterate meglumine produces a large magnetic moment and so a large local magnetic field, which can enhance the relaxation rate of nearby protons; as a result, the signal intensity of tissue images observed with magnetic resonance imaging (MRI) may be enhanced. Because this agent is preferentially taken up by normal functioning hepatocytes, normal hepatic tissue is enhanced with MRI while tumor tissue is unenhanced. In addition, because gadobenate dimeglumine is excreted in the bile, it may be used to visualize the biliary system using MRI.
Status:
US Approved Rx
(2019)
Source:
ANDA210016
(2019)
Source URL:
First approved in 1988
Source:
MAGNEVIST by BAYER HLTHCARE
Source URL:
Class (Stereo):
CHEMICAL (RACEMIC)
Conditions:
DOTAREM (Gadoterate Meglumine ) is a gadolinium-based contrast agent indicated for intravenous use with magnetic resonance imaging (MRI) in brain (intracranial), spine and associatedtissues in adult and pediatric patients (2 years of age and older) to detect and visualize areas with disruption of the blood brain barrier (BBB) and/or abnormal vascularity. Gadoterate Meglumine is a gadolinium chelate paramagnetic contrast agent. When placed in a magnetic field, gadoterate meglumine produces a large magnetic moment and so a large local magnetic field, which can enhance the relaxation rate of nearby protons; as a result, the signal intensity of tissue images observed with magnetic resonance imaging (MRI) may be enhanced. Because this agent is preferentially taken up by normal functioning hepatocytes, normal hepatic tissue is enhanced with MRI while tumor tissue is unenhanced. In addition, because gadobenate dimeglumine is excreted in the bile, it may be used to visualize the biliary system using MRI.
Status:
US Approved Rx
(2019)
Source:
ANDA210016
(2019)
Source URL:
First approved in 1988
Source:
MAGNEVIST by BAYER HLTHCARE
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Conditions:
DOTAREM (Gadoterate Meglumine ) is a gadolinium-based contrast agent indicated for intravenous use with magnetic resonance imaging (MRI) in brain (intracranial), spine and associatedtissues in adult and pediatric patients (2 years of age and older) to detect and visualize areas with disruption of the blood brain barrier (BBB) and/or abnormal vascularity. Gadoterate Meglumine is a gadolinium chelate paramagnetic contrast agent. When placed in a magnetic field, gadoterate meglumine produces a large magnetic moment and so a large local magnetic field, which can enhance the relaxation rate of nearby protons; as a result, the signal intensity of tissue images observed with magnetic resonance imaging (MRI) may be enhanced. Because this agent is preferentially taken up by normal functioning hepatocytes, normal hepatic tissue is enhanced with MRI while tumor tissue is unenhanced. In addition, because gadobenate dimeglumine is excreted in the bile, it may be used to visualize the biliary system using MRI.
Status:
US Approved Rx
(2019)
Source:
ANDA210016
(2019)
Source URL:
First approved in 1988
Source:
MAGNEVIST by BAYER HLTHCARE
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
DOTAREM (Gadoterate Meglumine ) is a gadolinium-based contrast agent indicated for intravenous use with magnetic resonance imaging (MRI) in brain (intracranial), spine and associatedtissues in adult and pediatric patients (2 years of age and older) to detect and visualize areas with disruption of the blood brain barrier (BBB) and/or abnormal vascularity. Gadoterate Meglumine is a gadolinium chelate paramagnetic contrast agent. When placed in a magnetic field, gadoterate meglumine produces a large magnetic moment and so a large local magnetic field, which can enhance the relaxation rate of nearby protons; as a result, the signal intensity of tissue images observed with magnetic resonance imaging (MRI) may be enhanced. Because this agent is preferentially taken up by normal functioning hepatocytes, normal hepatic tissue is enhanced with MRI while tumor tissue is unenhanced. In addition, because gadobenate dimeglumine is excreted in the bile, it may be used to visualize the biliary system using MRI.
Status:
US Approved Rx
(2019)
Source:
ANDA210016
(2019)
Source URL:
First approved in 1988
Source:
MAGNEVIST by BAYER HLTHCARE
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Conditions:
DOTAREM (Gadoterate Meglumine ) is a gadolinium-based contrast agent indicated for intravenous use with magnetic resonance imaging (MRI) in brain (intracranial), spine and associatedtissues in adult and pediatric patients (2 years of age and older) to detect and visualize areas with disruption of the blood brain barrier (BBB) and/or abnormal vascularity. Gadoterate Meglumine is a gadolinium chelate paramagnetic contrast agent. When placed in a magnetic field, gadoterate meglumine produces a large magnetic moment and so a large local magnetic field, which can enhance the relaxation rate of nearby protons; as a result, the signal intensity of tissue images observed with magnetic resonance imaging (MRI) may be enhanced. Because this agent is preferentially taken up by normal functioning hepatocytes, normal hepatic tissue is enhanced with MRI while tumor tissue is unenhanced. In addition, because gadobenate dimeglumine is excreted in the bile, it may be used to visualize the biliary system using MRI.
Status:
US Approved Rx
(2019)
Source:
ANDA210016
(2019)
Source URL:
First approved in 1988
Source:
MAGNEVIST by BAYER HLTHCARE
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Conditions:
DOTAREM (Gadoterate Meglumine ) is a gadolinium-based contrast agent indicated for intravenous use with magnetic resonance imaging (MRI) in brain (intracranial), spine and associatedtissues in adult and pediatric patients (2 years of age and older) to detect and visualize areas with disruption of the blood brain barrier (BBB) and/or abnormal vascularity. Gadoterate Meglumine is a gadolinium chelate paramagnetic contrast agent. When placed in a magnetic field, gadoterate meglumine produces a large magnetic moment and so a large local magnetic field, which can enhance the relaxation rate of nearby protons; as a result, the signal intensity of tissue images observed with magnetic resonance imaging (MRI) may be enhanced. Because this agent is preferentially taken up by normal functioning hepatocytes, normal hepatic tissue is enhanced with MRI while tumor tissue is unenhanced. In addition, because gadobenate dimeglumine is excreted in the bile, it may be used to visualize the biliary system using MRI.
Status:
US Approved Rx
(2019)
Source:
ANDA210016
(2019)
Source URL:
First approved in 1988
Source:
MAGNEVIST by BAYER HLTHCARE
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Conditions:
DOTAREM (Gadoterate Meglumine ) is a gadolinium-based contrast agent indicated for intravenous use with magnetic resonance imaging (MRI) in brain (intracranial), spine and associatedtissues in adult and pediatric patients (2 years of age and older) to detect and visualize areas with disruption of the blood brain barrier (BBB) and/or abnormal vascularity. Gadoterate Meglumine is a gadolinium chelate paramagnetic contrast agent. When placed in a magnetic field, gadoterate meglumine produces a large magnetic moment and so a large local magnetic field, which can enhance the relaxation rate of nearby protons; as a result, the signal intensity of tissue images observed with magnetic resonance imaging (MRI) may be enhanced. Because this agent is preferentially taken up by normal functioning hepatocytes, normal hepatic tissue is enhanced with MRI while tumor tissue is unenhanced. In addition, because gadobenate dimeglumine is excreted in the bile, it may be used to visualize the biliary system using MRI.